The effect of midazolam drug on the occurrence of restlessness and agitation in patients undergoing electroshock therapy
Phase 3
- Conditions
- Patients undergoing electroshock therapy.
- Registration Number
- IRCT20170108031818N3
- Lead Sponsor
- Gorgan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
The patient diagnosed with psychosis is indicated for ECT
Exclusion Criteria
Age range 18-75 years
Patient satisfaction to conduct research
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Restlessness and agitation. Timepoint: Twice a day at 8-10 and 16-18 for a maximum of 4 days. Method of measurement: The Richmond Agitation and Sedation Scale (RASS).
- Secondary Outcome Measures
Name Time Method Cardiovascular response of trauma patients in special surgery departments. Timepoint: Before and after each drug intervention. Method of measurement: Blood pressure with a blood pressure monitor device and the patient's pulse with a heart and breathing monitor with a manual counter in one minute.